A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin) In Patients With Advanced Solid Tumours.

Trial Profile

A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin) In Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Bevacizumab; Olaparib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2010 Actual end date changed from May 2009 to Nov 2009 as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top